We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Mo's Smoke-Free Vision vs. Cigarette Declines: Is Transition on Track?
Read MoreHide Full Article
Key Takeaways
Altria's cigarette shipments dropped 10.2% in Q2, with Marlboro's category share slipping to 41%.
on! nicotine pouch shipments climbed 26.5%, reaching 52.1M cans and 8.7% U.S. oral tobacco share.
Smokeable products delivered $2.9B OCI, showing cigarettes remain far more profitable than smoke-free.
Altria Group, Inc. ((MO - Free Report) ) continues to advance its smoke-free strategy. The second quarter of 2025 highlights the steep climb ahead. Domestic cigarette shipments in the smokeable products segment fell 10.2% year over year. Marlboro’s retail share of the total cigarette category slipped 0.9 points to 41%, though the brand held its ground in the premium tier, edging up 0.2 points to 59.5% both year over year and sequentially.
In contrast, smoke-free offerings, particularly on! nicotine pouches showed solid momentum. Shipments rose 26.5% to 52.1 million cans in the second quarter. The brand captured 8.7% of the total U.S. oral tobacco category, while the segment overall delivered double-digit adjusted operating companies income (“OCI”) growth with margins of 68.7%. Broader consumer engagement, through both in-person events and digital campaigns, also appears to be driving higher awareness and trial.
Even so, combustibles remain Altria’s economic anchor. The smokeable products segment generated $2.9 billion in adjusted OCI in the second quarter, with margins at 64.5%. That scale underscores how far smoke-free products must climb before they can meaningfully offset cigarette declines.
Overall, the quarter illustrates a company in transition. Cigarettes are shrinking, but still highly profitable. Oral nicotine is expanding, but from a much smaller base. Altria’s vision of “Moving Beyond Smoking” is progressing, though the pace remains gradual, and the balance of decline versus growth will continue to define its journey.
Altria and Competitors Advance in Smoke-Free Market
Philip Morris International Inc. ((PM - Free Report) ) presents a sharper contrast in smoke-free progress. In the second quarter of 2025, Philip Morris generated 41% of net revenues from smoke-free products, with an 11.8% increase in shipment volumes. Philip Morris also reported nicotine pouch shipments rising more than 40% in the United States, underscoring faster category adoption and stronger traction in reduced-risk offerings.
Turning Point Brands, Inc. ((TPB - Free Report) ) is accelerating its shift to modern oral, with the second quarter of 2025 revenues up 25% to $116.6 million. Modern Oral contributed $30.1 million (26% of sales), with white pouch sales rising nearly eightfold year over year. While legacy Stoker’s brands stayed resilient, Turning Point Brands raised full-year Modern Oral sales guidance to $100-$110 million. Turning Point Brands’ strong pouch momentum highlights its growing role in the smoke-free transition.
MO’s Price Performance, Valuation & Estimates
Shares of Altria have gained 0.8% in the past month against the industry’s decline of 3.2%.
Image Source: Zacks Investment Research
From a valuation standpoint, MO trades at a forward price-to-earnings ratio of 12.01X, down from the industry’s average of 14.99X.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for MO’s 2025 and 2026 earnings implies year-over-year growth of 5.3% and 2.9%, respectively.
Image: Bigstock
Mo's Smoke-Free Vision vs. Cigarette Declines: Is Transition on Track?
Key Takeaways
Altria Group, Inc. ((MO - Free Report) ) continues to advance its smoke-free strategy. The second quarter of 2025 highlights the steep climb ahead. Domestic cigarette shipments in the smokeable products segment fell 10.2% year over year. Marlboro’s retail share of the total cigarette category slipped 0.9 points to 41%, though the brand held its ground in the premium tier, edging up 0.2 points to 59.5% both year over year and sequentially.
In contrast, smoke-free offerings, particularly on! nicotine pouches showed solid momentum. Shipments rose 26.5% to 52.1 million cans in the second quarter. The brand captured 8.7% of the total U.S. oral tobacco category, while the segment overall delivered double-digit adjusted operating companies income (“OCI”) growth with margins of 68.7%. Broader consumer engagement, through both in-person events and digital campaigns, also appears to be driving higher awareness and trial.
Even so, combustibles remain Altria’s economic anchor. The smokeable products segment generated $2.9 billion in adjusted OCI in the second quarter, with margins at 64.5%. That scale underscores how far smoke-free products must climb before they can meaningfully offset cigarette declines.
Overall, the quarter illustrates a company in transition. Cigarettes are shrinking, but still highly profitable. Oral nicotine is expanding, but from a much smaller base. Altria’s vision of “Moving Beyond Smoking” is progressing, though the pace remains gradual, and the balance of decline versus growth will continue to define its journey.
Altria and Competitors Advance in Smoke-Free Market
Philip Morris International Inc. ((PM - Free Report) ) presents a sharper contrast in smoke-free progress. In the second quarter of 2025, Philip Morris generated 41% of net revenues from smoke-free products, with an 11.8% increase in shipment volumes. Philip Morris also reported nicotine pouch shipments rising more than 40% in the United States, underscoring faster category adoption and stronger traction in reduced-risk offerings.
Turning Point Brands, Inc. ((TPB - Free Report) ) is accelerating its shift to modern oral, with the second quarter of 2025 revenues up 25% to $116.6 million. Modern Oral contributed $30.1 million (26% of sales), with white pouch sales rising nearly eightfold year over year. While legacy Stoker’s brands stayed resilient, Turning Point Brands raised full-year Modern Oral sales guidance to $100-$110 million. Turning Point Brands’ strong pouch momentum highlights its growing role in the smoke-free transition.
MO’s Price Performance, Valuation & Estimates
Shares of Altria have gained 0.8% in the past month against the industry’s decline of 3.2%.
Image Source: Zacks Investment Research
From a valuation standpoint, MO trades at a forward price-to-earnings ratio of 12.01X, down from the industry’s average of 14.99X.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for MO’s 2025 and 2026 earnings implies year-over-year growth of 5.3% and 2.9%, respectively.
Image Source: Zacks Investment Research
Altria currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.